(Q40586841)

English

Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines

scientific article published on January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

based on heuristic

inferred from title

zoledronic acid

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Shinya Kimura

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Junya Kuroda

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Hidekazu Segawa

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Kiyoshi Sato

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Masaki Nogawa

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Takeshi Yuasa

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Taira Maekawa

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

79

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

37-43

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies

1 reference

https://api.crossref.org/works/10.1007%2FBF02983531

21 January 2018

Bisphosphonates induce apoptosis in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FBF02983531

21 January 2018

Combination Chemotherapy for Advanced Breast Cancer: Response and Effect on Survival

1 reference

https://api.crossref.org/works/10.1007%2FBF02983531

21 January 2018

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of apoptosis using 2′,2′difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bisphosphonate treatment inhibits the growth of prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pro-apoptotic effect of the CDK inhibitor p57(Kip2) on staurosporine-induced apoptosis in HeLa cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overview of bisphosphonates

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

1 reference

https://pubmed.ncbi.nlm.nih.gov/14979476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF02983531

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40586841&oldid=2203808483"